Adjuvant Ovarian Suppression in Premenopausal Breast Cancer […]Read More… from Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Juxtamembrane Mimic Peptide Loaded Injectable Sodium Alginate/Bioglass Bioactive Hydrogel for Suppressing Tumor Recurrence in Post-Breast-Conserving-Surgery Treatment […]Read More… from Juxtamembrane Mimic Peptide Loaded Injectable Sodium Alginate/Bioglass Bioactive Hydrogel for Suppressing Tumor Recurrence in Post-Breast-Conserving-Surgery Treatment
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer […]Read More… from Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling […]Read More… from Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer […]Read More… from Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer […]Read More… from Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer […]Read More… from Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer […]Read More… from Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
PAPP-A is a marker of aggressive breast cancer and promotes cancer progression in-vitro […]Read More… from PAPP-A is a marker of aggressive breast cancer and promotes cancer progression in-vitro
The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits […]Read More… from The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. […]Read More… from Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes […]Read More… from Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer […]Read More… from Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Adjuvant trastuzumab in HER2-positive breast cancer. […]Read More… from Adjuvant trastuzumab in HER2-positive breast cancer.
Breast-cancer adjuvant therapy with zoledronic acid. […]Read More… from Breast-cancer adjuvant therapy with zoledronic acid.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. […]Read More… from Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem) […]Read More… from Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. […]Read More… from Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. […]Read More… from Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Breast CancerBreast Cancer
Breast Cancer